{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:49:06Z","timestamp":1787320146352,"version":"build-2736575974"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,2,8]],"date-time":"2017-02-08T00:00:00Z","timestamp":1486512000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s10928-017-9509-1","type":"journal-article","created":{"date-parts":[[2017,2,8]],"date-time":"2017-02-08T09:45:23Z","timestamp":1486547123000},"page":"143-151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4493-4652","authenticated-orcid":false,"given":"Laura L.","family":"Kovanda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit V.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,8]]},"reference":[{"issue":"3","key":"9509_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1086\/525258","volume":"46","author":"TJ Walsh","year":"2008","unstructured":"Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF, Infectious Diseases Society of A (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46(3):327\u2013360. doi: 10.1086\/525258","journal-title":"Clin Infect Dis"},{"issue":"4","key":"9509_CR2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1469-0691.2008.01984.x","volume":"14","author":"F Lanternier","year":"2008","unstructured":"Lanternier F, Lortholary O (2008) Liposomal amphotericin B: what is its role in 2008? Clin Microbiol Infect 14(4):71\u201383","journal-title":"Clin Microbiol Infect"},{"key":"9509_CR3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jinf.2014.01.007","volume":"68","author":"D Enoch","year":"2014","unstructured":"Enoch D, Idris S, Aliyu S, Micallef C, Sule O, Karas J (2014) Micafungin for the treatment of invasive aspergillosis. J Infect 68:507\u2013526","journal-title":"J Infect"},{"issue":"7","key":"9509_CR4","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/bmt.2009.334","volume":"45","author":"R Herbrecht","year":"2010","unstructured":"Herbrecht R, Maertens J, Baila L, Aoun M, Heinz W, Martino R, Schwartz S, Ullmann A, Meert L, Paesmans M, Marchetti O, Akan H, Ameye L, Shivaprakash M, Viscoli C (2010) Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transpl 45(7):1227\u20131233. doi: 10.1038\/bmt.2009.334","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"9509_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ijantimicag.2014.05.019","volume":"44","author":"M Dolton","year":"2014","unstructured":"Dolton M, McLachlan A (2014) Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity. Int J Antimicrob Agents 44(3):183\u2013193. doi: 10.1016\/j.ijantimicag.2014.05.019","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"9509_CR6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/QCO.0000000000000005","volume":"26","author":"E Vermeulen","year":"2013","unstructured":"Vermeulen E, Lagrou K, Verweij P (2013) Azole resistance in Aspergillus fumigatus: a growing health concern. Curr Opin Infect Dis 26(6):493\u2013500","journal-title":"Curr Opin Infect Dis"},{"issue":"12","key":"9509_CR7","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1128\/IAI.62.12.5424-5433.1994","volume":"62","author":"J Latge","year":"1994","unstructured":"Latge J, Kobayashi H, Debeaupuis J, Diaquin M, Sarfati J, Wieruszeski J, Parra E, Bouchara J, Fournet B (1994) Chemical and immunological characterization of the extracellular galactomannan of Aspergillus fumigatus. Infect Immun 62(12):5424\u20135433","journal-title":"Infect Immun"},{"issue":"6","key":"9509_CR8","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1128\/IAI.60.6.2237-2245.1992","volume":"60","author":"D Stynen","year":"1992","unstructured":"Stynen D, Sarfati J, Goris A, Prevost MC, Lesourd M, Kamphuis H, Darras V, Latge JP (1992) Rat monoclonal antibodies against Aspergillus galactomannan. Infect Immun 60(6):2237\u20132245","journal-title":"Infect Immun"},{"key":"9509_CR9","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1086\/503427","volume":"42","author":"C Pfeiffer","year":"2006","unstructured":"Pfeiffer C, Fine J, Safdar S (2006) Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 42:1417\u20131427","journal-title":"Clin Infect Dis"},{"issue":"4","key":"9509_CR10","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.diagmicrobio.2011","volume":"72","author":"M Mikulska","year":"2012","unstructured":"Mikulska M, Furfaro E, Del BV, Gualandi F, Raiola A, Molinari M, Gritti P, Sanguinetti M, Posteraro B, Bacigalupo A, Viscoli C (2012) Galactomannan testing might be useful for early diagnosis of fusariosis. Microbiol Infect Dis 72(4):367\u2013369. doi: 10.1016\/j.diagmicrobio.2011","journal-title":"Microbiol Infect Dis"},{"issue":"3","key":"9509_CR11","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1128\/JCM.05946-11","volume":"50","author":"A Tortorano","year":"2012","unstructured":"Tortorano A, Esposto M, Prigitano A, Grancini A, Ossi C, Cavanna C, Cascio G (2012) Cross-reactivity of Fusarium spp. in the Aspergillus galactomannan enzyme-linked immunosorbent assay. J Clin Microbiol 50(3):1051\u20131053. doi: 10.1128\/JCM.05946-11","journal-title":"J Clin Microbiol"},{"issue":"12","key":"9509_CR12","doi-asserted-by":"publisher","first-page":"4593","DOI":"10.1128\/JCM.39.12.4593-4594.2001","volume":"39","author":"C Kauffmann-Lacroix","year":"2001","unstructured":"Kauffmann-Lacroix C, Rodier M, Jacquemin J (2001) Detection of galactomannan for diagnosis of fungal rhinosinusitis. J Clin Microbiol 39(12):4593\u20134594. doi: 10.1128\/JCM.39.12.4593-4594.2001","journal-title":"J Clin Microbiol"},{"issue":"1","key":"9509_CR13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1128\/JCM.35.1.257-260.1997","volume":"35","author":"C Swanink","year":"1997","unstructured":"Swanink C, Meis J, Rijs A, Donnelly J, Verweij P (1997) Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan. J Clin Microbiol 35(1):257\u2013260","journal-title":"J Clin Microbiol"},{"issue":"14","key":"9509_CR14","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1097\/QAD.0b013e3282eeb413","volume":"21","author":"Y Huang","year":"2007","unstructured":"Huang Y, Hung C, Hsueh P (2007) Aspergillus galactomannan antigenemia in penicilliosis marneffei. AIDS 21(14):1990\u20131991","journal-title":"AIDS"},{"key":"9509_CR15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1086\/510535","volume":"195","author":"W Hope","year":"2007","unstructured":"Hope W, Kruhlak M, Lyman C, Petraitiene R, Petraitis V, Francesconi A, Kasai A, Mickiene D, Sein T, Peter J, Kelaher A, Hughes J, Cotton M, Cotten C, Bacher J, Tripathi S, Bermudez L, Maugel T, Zerfas P, Wingard J, Drusano G, Walsh T (2007) Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. J Infect Dis 195:455\u2013466","journal-title":"J Infect Dis"},{"key":"9509_CR16","doi-asserted-by":"crossref","unstructured":"Kovanda L, Petraitiene R, Petraitis V, Walsh T, Desai A, Bonate P, Hope W (2016) Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints. J Antimicrob Chemother pii: dkw098","DOI":"10.1093\/jac\/dkw098"},{"issue":"11","key":"9509_CR17","doi-asserted-by":"publisher","first-page":"4879","DOI":"10.1128\/AAC.00673-10","volume":"54","author":"WW Hope","year":"2010","unstructured":"Hope WW, Petraitis V, Petraitiene R, Aghamolla T, Bacher J, Walsh TJ (2010) The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1\u21923) beta-d-glucan and consequences of delayed antifungal therapy. Antimicrob Agents Chemother 54(11):4879\u20134886. doi: 10.1128\/AAC.00673-10","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"9509_CR18","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/infdis\/155.5.1005","volume":"155","author":"J Bennett","year":"1987","unstructured":"Bennett J, Friedman M, Dupont B (1987) Receptor-mediated clearance of Aspergillus galactomannan. J Infect Dis 155(5):1005\u20131010","journal-title":"J Infect Dis"},{"key":"9509_CR19","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1093\/mmy\/myu019","volume":"52","author":"W Duettmann","year":"2014","unstructured":"Duettmann W, Koidl C, Troppan K, Seeber K, Buzina W, Wolfler A, Wagner J, Krause R, Hoenigl M (2014) Serum and urine galactomannan testing for screening in patients with hematological malignancies. Med Mycol 52:647\u2013652. doi: 10.1093\/mmy\/myu019","journal-title":"Med Mycol"},{"issue":"1","key":"9509_CR20","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1080\/13693780802213340","volume":"47","author":"K Clemons","year":"2009","unstructured":"Clemons K, Stevens D (2009) Conventional or molecular measurement of Aspergillus load. Med Mycol 47(1):S132\u2013S137","journal-title":"Med Mycol"},{"issue":"3","key":"9509_CR21","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1128\/AAC.45.3.857-869.2001","volume":"45","author":"R Petraitiene","year":"2001","unstructured":"Petraitiene R, Petraitis V, Groll AH, Sein T, Piscitelli S, Candelario M, Field-Ridley A, Avila N, Bacher J, Walsh TJ (2001) Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother 45(3):857\u2013869. doi: 10.1128\/AAC.45.3.857-869.2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"9509_CR22","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1128\/aac.48.4.1188-1196.2004","volume":"48","author":"R Petraitiene","year":"2004","unstructured":"Petraitiene R, Petraitis V, Lyman CA, Groll AH, Mickiene D, Peter J, Bacher J, Roussillon K, Hemmings M, Armstrong D, Avila NA, Walsh TJ (2004) Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 48(4):1188\u20131196. doi: 10.1128\/aac.48.4.1188-1196.2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"9509_CR23","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1128\/AAC.02665-15","volume":"60","author":"V Petraitis","year":"2016","unstructured":"Petraitis V, Petraitiene R, Moradi P, Strauss G, Katragkou A, Kovanda L, Hope W, Walsh T (2016) Pharmacokinetics and concentration-dependent efficacy of isavuconazole for treatment of experimental invasive pulmonary aspergillosis. Antimicrob Agents Chemother 60(5):2718\u20132726","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"9509_CR24","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/jac\/dkl015","volume":"57","author":"W Vianen van","year":"2006","unstructured":"van Vianen W, de Marie S, ten Kate MT, Mathot RA, Bakker-Woudenberg IA (2006) Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. J Antimicrob Chemother 57(4):732\u2013740. doi: 10.1093\/jac\/dkl015","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"9509_CR25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jinf.2005.10.015","volume":"53","author":"E Sionov","year":"2006","unstructured":"Sionov E, Mendlovic S, Segal E (2006) Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis. J Infect 53(2):131\u2013139. doi: 10.1016\/j.jinf.2005.10.015","journal-title":"J Infect"},{"issue":"6","key":"9509_CR26","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1128\/aac.46.6.1857-1869.2002","volume":"46","author":"V Petraitis","year":"2002","unstructured":"Petraitis V, Petraitiene R, Groll AH, Roussillon K, Hemmings M, Lyman CA, Sein T, Bacher J, Bekersky I, Walsh TJ (2002) Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 46(6):1857\u20131869. doi: 10.1128\/aac.46.6.1857-1869.2002","journal-title":"Antimicrob Agents Chemother"},{"key":"9509_CR27","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1086\/375420","volume":"187","author":"V Petraitis","year":"2003","unstructured":"Petraitis V, Petraitiene R, Sarafandi A, Kelaher A, Lyman C, Casler H, Sein T, Groll A, Bacher J, Avila N, Walsh T (2003) Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 187:1834\u20131843","journal-title":"J Infect Dis"},{"issue":"1","key":"9509_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1128\/aac.46.1.12-23.2002","volume":"46","author":"R Petraitiene","year":"2002","unstructured":"Petraitiene R, Petraitis V, Groll AH, Sein T, Schaufele RL, Francesconi A, Bacher J, Avila NA, Walsh TJ (2002) Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 46(1):12\u201323. doi: 10.1128\/aac.46.1.12-23.2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"9509_CR29","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1128\/AAC.04723-14","volume":"59","author":"Z Al-Nakeeb","year":"2015","unstructured":"Al-Nakeeb Z, Petraitis V, Goodwin J, Petraitiene R, Walsh TJ, Hope WW (2015) Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus. Antimicrob Agents Chemother 59(5):2735\u20132745. doi: 10.1128\/AAC.04723-14","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"9509_CR30","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1128\/AAC.00662-11","volume":"56","author":"J Meletiadis","year":"2012","unstructured":"Meletiadis J, Al-Saigh R, Velegraki A, Walsh T, Roilides E, Zerva L (2012) Pharmacodynamics effect of simulated standard dose of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic\/pharmacodynamic model. Antimicrob Agents Chemother 56(1):403\u2013410","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"9509_CR31","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1128\/AAC.02484-12","volume":"57","author":"R Al-Saigh","year":"2013","unstructured":"Al-Saigh R, Siopi M, Siafakas N, Velegraki A, Zerva L, Meletiadis J (2013) Single-dose pharmacodynamics of amphotericin B against Aspergillus species in an in vitro pharmacokinetic\/pharmacodynamic model. Antimicrob Agents Chemother 57(8):3713\u20133718. doi: 10.1128\/AAC.02484-12","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"9509_CR32","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1128\/AAC.02661-13","volume":"58","author":"A Elefanti","year":"2014","unstructured":"Elefanti A, Mouton JW, Verweij PE, Zerva L, Meletiadis J (2014) Susceptibility breakpoints for amphotericin B and Aspergillus species in an in vitro pharmacokinetic-pharmacodynamic model simulating free-drug concentrations in human serum. Antimicrob Agents Chemother 58(4):2356\u20132362. doi: 10.1128\/AAC.02661-13","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"9509_CR33","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1086\/377210","volume":"188","author":"T Walsh","year":"2003","unstructured":"Walsh T, Petraitis V, Petraitiene R, Field-Ridley A, Sutton D, Ghannoum M, Sein T, Schaufele R, Peter J, Bacher J, Casler H, Armstrong D, Espinel-Ingroff A, Rinaldi M, Lyman C (2003) Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis 188(2):305\u2013319","journal-title":"J Infect Dis"},{"issue":"3","key":"9509_CR34","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1128\/AAC.01436-12","volume":"57","author":"V Salas","year":"2013","unstructured":"Salas V, Javier Pastor F, Sutton DA, Calvo E, Mayayo E, Fothergill AW, Rinaldi MG, Guarro J (2013) MIC values of voriconazole are predictive of treatment results in murine infections by Aspergillus terreus species complex. Antimicrob Agents Chemother 57(3):1532\u20131534","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"9509_CR35","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1093\/infdis\/jir023","volume":"203","author":"SJ Howard","year":"2011","unstructured":"Howard SJ, Lestner JM, Sharp A, Gregson L, Goodwin J, Slater J, Majithiya JB, Warn PA, Hope WW (2011) Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. J Infect Dis 203(9):1324\u20131332. doi: 10.1093\/infdis\/jir023","journal-title":"J Infect Dis"},{"issue":"3","key":"9509_CR36","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/infdis\/jis372","volume":"206","author":"AR Jeans","year":"2012","unstructured":"Jeans AR, Howard SJ, Al-Nakeeb Z, Goodwin J, Gregson L, Majithiya JB, Lass-Florl C, Cuenca-Estrella M, Arendrup MC, Warn PA, Hope WW (2012) Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints. J Infect Dis 206(3):442\u2013452. doi: 10.1093\/infdis\/jis372","journal-title":"J Infect Dis"},{"issue":"8","key":"9509_CR37","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1128\/AAC.00141-12","volume":"56","author":"Z Al-Nakeeb","year":"2012","unstructured":"Al-Nakeeb Z, Sudan A, Jeans AR, Gregson L, Goodwin J, Warn PA, Felton TW, Howard SJ, Hope WW (2012) Pharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole-resistant infection and utility of airway administration. Antimicrob Agents Chemother 56(8):4146\u20134153. doi: 10.1128\/AAC.00141-12","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"9509_CR38","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/jac\/dku484","volume":"70","author":"M Siopi","year":"2014","unstructured":"Siopi M, Mavridou E, Mouton J, Verweij P, Zerva L, Meletiadis J (2014) Susceptibility breakpoints and target value for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic\/pharmacodynamic model. J Antimicrob Chemother 70(2):634\u2013635","journal-title":"J Antimicrob Chemother"},{"key":"9509_CR39","unstructured":"Box H, Gregson L, Livermore J, Felton TW, Howard SJ, Whalley S, Goodwin J, Johnson A, McEntee L, Hope WW (2014) Pharmacodynamics of isavuconazole (ISA) in a dynamic in vitro model of invasive pulmonary aspergillosis. Paper presented at the ICAAC, Washington, DC"},{"issue":"2","key":"9509_CR40","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1128\/AAC.00931-09","volume":"54","author":"E Mavridou","year":"2010","unstructured":"Mavridou E, Bruggemann RJ, Melchers WJ, Mouton JW, Verweij PE (2010) Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother 54(2):860\u2013865. doi: 10.1128\/AAC.00931-09","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"9509_CR41","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1128\/AAC.01364-15","volume":"60","author":"H Box","year":"2015","unstructured":"Box H, Livermore J, Johnson A, McEntee L, Felton TW, Whalley S, Goodwin J, Hope WW (2015) Pharmacodynamics of Isavuconazole in a dynamic in vitro model of invasive pulmonary Aspergillosis. Antimicrob Agents Chemother 60(1):278\u2013287. doi: 10.1128\/AAC.01364-15","journal-title":"Antimicrob Agents Chemother"},{"key":"9509_CR42","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0163-4453(97)90833-1","volume":"35","author":"S Bretagne","year":"1997","unstructured":"Bretagne S, Marmorat-Khuong A, Kuentz M, Latge J, Bart-Delabesse E, Cordonnier C (1997) Serum Aspergillus galactomannan antigen testing by sandwich ELISA: practical use in neutropenic patients. J Infect 35:7\u201315","journal-title":"J Infect"},{"key":"9509_CR43","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1034\/j.1399-3062.2000.020307.x","volume":"2","author":"M Machetti","year":"2000","unstructured":"Machetti M, Zotti M, Veroni L, Mordini N, Van Lint M, Bacigalupo A, Paola D, Viscoli C (2000) Antigen detection in the diagnosis and management of a patient with probable cerebral aspergillosis treated with voriconazole. Transpl Infect Dis 2:140\u2013144","journal-title":"Transpl Infect Dis"},{"key":"9509_CR44","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1099\/jmm.0.023630-0","volume":"59","author":"E Mokaddas","year":"2010","unstructured":"Mokaddas E, Burhamah M, Ahmad S, Khan Z (2010) Invasive pulmonary aspergillosis due to Aspergillus terreus: value of DNA, galactomannan and (1\u21923)-beta-D-glucan detection in serum samples as an adjunct to diagnosis. J Med Microbiol 59:1519\u20131523","journal-title":"J Med Microbiol"},{"issue":"1","key":"9509_CR45","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13052-016-0239-6","volume":"42","author":"TF Weng","year":"2016","unstructured":"Weng TF, Wu KH, Wu HP, Peng CT, Chao YH (2016) Changes of serum Aspergillus galactomannan during hematopoietic stem cell transplantation in children with prior invasive aspergillosis. Ital J Pediatr 42(1):30. doi: 10.1186\/s13052-016-0239-6","journal-title":"Ital J Pediatr"},{"issue":"2","key":"9509_CR46","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/cncr.24022","volume":"115","author":"J Maertens","year":"2009","unstructured":"Maertens J, Buve K, Theunissen K, Meersseman W, Verbeken E, Verhoef G, Van Eldere J, Lagrou K (2009) Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer 115(2):355\u2013362. doi: 10.1002\/cncr.24022","journal-title":"Cancer"},{"issue":"7","key":"9509_CR47","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/cid\/cir441","volume":"53","author":"SA Nouer","year":"2011","unstructured":"Nouer SA, Nucci M, Kumar NS, Grazziutti M, Barlogie B, Anaissie E (2011) Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition. Clin Infect Dis 53(7):671\u2013676. doi: 10.1093\/cid\/cir441","journal-title":"Clin Infect Dis"},{"issue":"4","key":"9509_CR48","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/cncr.22863","volume":"110","author":"G Woods","year":"2007","unstructured":"Woods G, Miceli M, Grazziutti M, Zhao W, Barlogie B, Anaissie E (2007) Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. Cancer 110(4):830\u2013834","journal-title":"Cancer"},{"key":"9509_CR49","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1086\/528714","volume":"46","author":"M Miceli","year":"2008","unstructured":"Miceli M, Grazziutti M, Woods G, Zhao W, Kocoglu M, Barlogie B, Anaissie A (2008) Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis 46:1412\u20131422","journal-title":"Clin Infect Dis"},{"issue":"4","key":"9509_CR50","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1128\/JCM.02281-09","volume":"48","author":"S Koo","year":"2010","unstructured":"Koo S, Bryar J, Baden L, Marty F (2010) Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J Clin Microbiol 48(4):1255\u20131260. doi: 10.1128\/JCM.02281-09","journal-title":"J Clin Microbiol"},{"key":"9509_CR51","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1086\/339324","volume":"34","author":"F Boutboul","year":"2002","unstructured":"Boutboul F, Alberti C, Leblanc T, Sulahian A, Gluckman E, Derouin F, Ribaud P (2002) Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis 34:939\u2013943","journal-title":"Clin Infect Dis"},{"issue":"2","key":"9509_CR52","doi-asserted-by":"publisher","first-page":"e90176","DOI":"10.1371\/journal.pone.0090176","volume":"9","author":"LY Chai","year":"2014","unstructured":"Chai LY, Kullberg BJ, Earnest A, Johnson EM, Teerenstra S, Vonk AG, Schlamm HT, Herbrecht R, Netea MG, Troke PF (2014) Voriconazole or amphotericin B as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosis. PLoS ONE 9(2):e90176. doi: 10.1371\/journal.pone.0090176","journal-title":"PLoS ONE"},{"issue":"6","key":"9509_CR53","doi-asserted-by":"publisher","first-page":"e0129022","DOI":"10.1371\/journal.pone.0129022","volume":"10","author":"D Neofytos","year":"2015","unstructured":"Neofytos D, Railkar R, Mullane KM, Fredricks DN, Granwehr B, Marr KA, Almyroudis NG, Kontoyiannis DP, Maertens J, Fox R, Douglas C, Iannone R, Kauh E, Shire N (2015) Correlation between circulating fungal biomarkers and clinical outcome in invasive aspergillosis. PLoS ONE 10(6):e0129022. doi: 10.1371\/journal.pone.0129022","journal-title":"PLoS ONE"},{"issue":"6","key":"9509_CR54","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/mmy\/myv034","volume":"53","author":"R Petraitiene","year":"2015","unstructured":"Petraitiene R, Petraitis V, Bacher JD, Finkelman MA, Walsh TJ (2015) Effects of host response and antifungal therapy on serum and BAL levels of galactomannan and (1\u21923)-beta-D-glucan in experimental invasive pulmonary aspergillosis. Med Mycol 53(6):558\u2013568. doi: 10.1093\/mmy\/myv034","journal-title":"Med Mycol"},{"issue":"4","key":"9509_CR55","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1128\/AAC.03023-15","volume":"60","author":"L Huureman","year":"2016","unstructured":"Huureman L, Neely M, Veringa A, Perez F, Ramos-Martin V, Tissing W, Alffenaar J, Hope W (2016) Pharmacodynamics of voriconazole in children: further steps along the path to true individualized therapy. Antimicrob Agents Chemother 60(4):2336\u20132342","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"9509_CR56","doi-asserted-by":"publisher","first-page":"e87784","DOI":"10.1371\/journal.pone.0087784","volume":"9","author":"M Nucci","year":"2014","unstructured":"Nucci M, Carlesse F, Cappellano P, Varon AG, Seber A, Garnica M, Nouer SA, Colombo AL (2014) Earlier diagnosis of invasive fusariosis with Aspergillus serum galactomannan testing. PLoS ONE 9(1):e87784. doi: 10.1371\/journal.pone.0087784","journal-title":"PLoS ONE"},{"issue":"1","key":"9509_CR57","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3760\/cma.j.issn.0366-6999.20131651","volume":"127","author":"H Hangyong","year":"2014","unstructured":"Hangyong H, Qian L, Shuo C, Lin D, Bing S, Fang L, Qingyuan Z (2014) Prognostic value of serum galactomannan index in critically ill patients with chronic obstructive pulmonary disease at risk of invasive pulmonary aspergillosis. Chin Med J 127(1):23\u201328. doi: 10.3760\/cma.j.issn.0366-6999.20131651","journal-title":"Chin Med J"},{"issue":"7","key":"9509_CR58","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1128\/CVI.00068-08","volume":"15","author":"C Thornton","year":"2008","unstructured":"Thornton C (2008) Development of an immunochromatographic lateral-flow device for rapid serodiagnosis of invasive aspergillosis. Clin Vaccine Immunol 15(7):1095\u20131105. doi: 10.1128\/CVI.00068-08","journal-title":"Clin Vaccine Immunol"},{"issue":"5","key":"9509_CR59","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1128\/JCM.02838-12","volume":"51","author":"K Heer de","year":"2013","unstructured":"de Heer K, van der Schee M, Zwinderman K, van den Berk I, Visser C, van Oers R, Sterk P (2013) Electronic nose technology for detection of invasive pulmonary aspergillosis in prolonged chemotherapy-induced neutropenia: a proof-of-principle study. J Clin Microbiol 51(5):1490\u20131495. doi: 10.1128\/JCM.02838-12","journal-title":"J Clin Microbiol"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-017-9509-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10928-017-9509-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-017-9509-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T23:21:44Z","timestamp":1601594504000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10928-017-9509-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,8]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["9509"],"URL":"https:\/\/doi.org\/10.1007\/s10928-017-9509-1","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,8]]}}}